貨號(hào)：GS40453

Nadecnemab is a human IgG4-kappa monoclonal antibody that specifically targets GFRA3 (GDNF family receptor alpha 3), a cell-surface receptor for the glial cell line-derived neurotrophic factor (GDNF) family. As an IgG4 isotype, it is designed to minimize effector functions (e.g., ADCC) and focus on receptor modulation. GFRA3 is involved in pain signaling and joint homeostasis. By binding to GFRA3, nadecnemab aims to inhibit its activation and downstream signaling pathways, thereby reducing pain and potentially modifying disease progression. It is being developed for the treatment of knee osteoarthritis (OA) and associated chronic pain.